Mark Sculpher, Neil Hawkins
and members of the HTA SIG
This 2-day course will provide an introduction to the methods of health technology assessment. There will be a focus on how to estimate the costs and benefits of new interventions and analysis undertaken to support decisions about whether new interventions should be funded by health systems. The first day will include sessions on policy context and basic economic evaluation methods, as well as lectures on health measurement and valuation for HTA, evidence synthesis and decision analysis. There will also be exercises to confirm participants’ understanding of key concepts. The second day will focus on sharing case studies and discussing key statistical challenges in HTA. Attendees will be encouraged to share their own HTA experiences.
The following topics will be covered: • HTA Policy
• Methods of economic evaluation
• Critical review of HTA publications
• Evidence synthesis
• Measuring and valuing health
• HTA decision models
• Industry HTA case studies
• Key statistical challenges in HTA
Course runs from: 10:00 – 18:00 (registration from 9:30) on Day 1
09:00 – 15:30 on Day 2.
Before 23rd December 2016
£495 + VAT
£570 + VAT (includes PSI membership for 1 year)
After 23rd December 2016
Non - Members
£670 + VAT (includes PSI membership for 1 year)
Registration costs (includes lunch and refreshments)
PSI are holding a limited number of hotel rooms at an extra cost until the 23rd December 2016 which will be allocated on a first come first served basis. Please contact the PSI Secretariat for more information.
Registration is now closed. Please contact the PSI Secretariat for late registrations.
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.